Valuation: Alvotech

Market Cap 125.82Cr 110.17Cr 101.7Cr 95Cr 178.78Cr 12TCr 182.85Cr 1.22TCr 472.47Cr 5.87TCr 472.5Cr 462.13Cr 20TCr P/E 2026 *
9.3x
P/E 2027 * 8.52x
Enterprise Value 235.72Cr 206.39Cr 190.54Cr 177.93Cr 334.94Cr 22TCr 342.57Cr 2.29TCr 885.16Cr 11TCr 885.21Cr 865.79Cr 38TCr EV / Sales 2026 *
3.55x
EV / Sales 2027 * 3x
Free-Float
41.72%
Yield 2026 *
-
Yield 2027 * -
1 day-5.95%
1 week-4.66%
Current month+3.57%
1 month+3.57%
3 months+11.90%
6 months-29.98%
Current year-32.16%
1 week 3.45
Extreme 3.45
3.77
1 month 2.94
Extreme 2.94
4.59
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.94
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
01/04Free

Chief Executive Officer

1,17,271 0.0355%
01/04Buy

Founder

3,18,000 0.0963%
01/04Sell

Founder

3,18,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-5.95%-4.66%-61.93%-49.57% 125.82Cr
+1.04%+5.94%-3.40%+2.32% 4.66TCr
+5.79%+16.17%+421.86%+634.63% 4.1TCr
+1.12%+15.18%+22.74%-12.71% 3.23TCr
+3.61%+6.69%+20.23%+62.38% 3.22TCr
+8.02%+6.35%+17.67%+34.73% 2.55TCr
+1.13%+15.66% - - 1.64TCr
+1.45%+17.35%+72.11%+127.60% 1.53TCr
+0.21%+4.72%+13.04%+17.47% 1.36TCr
-0.60%+6.32%+102.74%+96.28% 1.33TCr
Average +1.58%+9.30%+67.23%+101.46% 2.37TCr
Weighted average by Cap. +2.83%+11.46%+97.36%+144.71%

Financials

2026 *2027 *
Net sales 66Cr 58Cr 54Cr 50Cr 94Cr 6.27TCr 96Cr 645.33Cr 249.13Cr 3.09TCr 249.14Cr 243.68Cr 11TCr 79Cr 69Cr 64Cr 60Cr 112.59Cr 7.49TCr 115.15Cr 770.74Cr 297.54Cr 3.7TCr 297.56Cr 291.03Cr 13TCr
Net income 16Cr 14Cr 13Cr 12Cr 23Cr 1.56TCr 24Cr 160.46Cr 62Cr 769.38Cr 62Cr 61Cr 2.67TCr 13Cr 12Cr 11Cr 10Cr 19Cr 1.27TCr 19Cr 130.4Cr 50Cr 625.26Cr 50Cr 49Cr 2.17TCr
Net Debt 109.9Cr 96Cr 89Cr 83Cr 156.16Cr 10TCr 159.72Cr 1.07TCr 412.69Cr 5.13TCr 412.71Cr 403.66Cr 18TCr 111.94Cr 98Cr 90Cr 84Cr 159.06Cr 11TCr 162.68Cr 1.09TCr 420.36Cr 5.22TCr 420.38Cr 411.16Cr 18TCr
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
29/26/29 $3.720 +1.09% 6,90,356
26/26/26 $3.680 +5.75% 9,91,865
25/26/25 $3.480 -5.95% 10,88,290
24/26/24 $3.700 0.00% 7,87,083
23/26/23 $3.700 +1.37% 7,87,899
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.720USD
Average target price
14.60USD
Spread / Average Target
+292.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock